CD38 and AL amyloidosis: Currently, there are two approved anti-CD38 monoclonal antibody treatments (Daratumumab and Isatuximab) and one in clinical trials (MOR202) to treat multiple myeloma; however, these drugs do not inhibit the ectoenzymatic activity of CD38, rather they induce antibody-dependent cell-mediated cytotoxicity[117-119].